AKT1 and endometrial cancer: In endometrial cancers, the knockdown of YTHDF2, a ‘reader’ protein that acts to promote the decay of its target mRNAs, can impede the decay of mTORC2, thus activating the AKT pathway [25], which is also known to be triggered in EMs [27].